Patient Derived Xenograft/PDX Models Market by Application (Biomarker Analysis and Pre-Clinical Drug Development), Type (Mouse & Rat), Tumor Type (Gynecological, Gastrointestinal, Respiratory), End User (Pharma & Biotech, CRO) – 2023 to 2028

SKU: GMS-2020

Format: PDF

Overall Rating
4.5/5

OVERVIEW

A recent report by Global Market Studies has revealed that the Patient-Derived Xenograft (PDX) Model Market in terms of revenue is estimated to reach $410 million in 2023 and will  reach a revenue of $850 million by 2028, growing at a CAGR of 15% to 2028.

The Patient-Derived Xenograft (PDX) Model Market pertains to a specialized sector within preclinical cancer research and drug development. It involves the transplantation of human tumor tissue, obtained directly from patients, into immunodeficient mice or other animal models. This creates living models that closely mimic the characteristics of the patient’s tumor, enabling researchers to study cancer behavior, test potential treatments, and advance the development of personalized medicine. The market encompasses services, products, and solutions related to the establishment, maintenance, and utilization of PDX models, contributing significantly to the field of oncology research and the development of tailored cancer therapies.

The Patient-Derived Xenograft (PDX) Model Market is primarily propelled by the imperative for personalized medicine and expedited drug development. Key drivers encompass the need to bridge the gap between preclinical and clinical research, enabling patient-specific therapy testing. Offerings include patient-derived tumor models, integration of omics data for comprehensive insights, and expansion into various therapeutic areas. These advancements foster innovation in oncology and beyond. PDX models also contribute to understanding tumor heterogeneity and drug resistance, ultimately shaping a more precise and effective healthcare landscape. In sum, the market’s core drivers and offerings drive forward the realms of personalized medicine, pharmaceutical research, and translational innovation.

Market Dynamics

Drivers:

The Patient-Derived Xenograft (PDX) Model Market is driven by several key factors. Firstly, there’s a growing demand for personalized cancer treatments, with PDX models enabling the testing of individual patient responses to various therapies. Additionally, traditional cell line models often fail to mimic the complexity of human tumors, enhancing the relevance of PDX models in oncology research. The global surge in cancer cases further propels the adoption of PDX models as researchers seek more accurate representations of patient-specific tumor behavior. Lastly, pharmaceutical companies and research institutions increasingly rely on PDX models to accelerate drug development, fostering innovation in precision medicine and cancer therapeutics. These drivers collectively underscore the growing significance of PDX models in advancing cancer research and treatment.

Opportunities:

The Patient-Derived Xenograft (PDX) Model Market offers a diverse range of offerings crucial for advancing cancer research and personalized medicine. Key offerings encompass the development and maintenance of PDX models, where human tumor tissues are transplanted into immunodeficient animals, creating living avatars of individual patient tumors. PDX model banks and associated data repositories enable researchers to access a wide variety of well-characterized models, enhancing the efficiency of oncology research. Additionally, services for drug efficacy testing, treatment response evaluation, and in-depth analysis of tumor behavior in a preclinical setting are vital for pharmaceutical companies and research institutions. The market also includes solutions for biobanking and data management, ensuring the secure storage and retrieval of PDX model samples and associated patient data. In essence, these offerings empower researchers and clinicians with essential tools to better understand cancer, optimize treatment strategies, and advance the field of oncology.

Restraints & Challenges:

The Patient-Derived Xenograft (PDX) Model Market faces several restraints and challenges. Firstly, the complex and costly process of establishing and maintaining PDX models can limit accessibility for smaller research institutions and companies. The time required for model development may not align with the urgency of certain research projects. Ethical considerations surrounding the use of animals in research pose regulatory and public relations challenges. Additionally, ensuring model reproducibility and reliability is paramount due to potential discrepancies between PDX models and original patient tumors. The variability and heterogeneity in human tumors further emphasize the need for careful validation and data interpretation. These challenges underscore the importance of continuous improvements and standardization within the PDX model field to fully harness their potential in advancing cancer research and personalized medicine.

Regional Information:

The Patient-Derived Xenograft (PDX) Model Market exhibits notable regional variations in adoption and research intensity. In North America, particularly the United States, PDX models are extensively used in preclinical research and oncology studies, supported by a robust pharmaceutical industry and research infrastructure. Europe, including the United Kingdom, France, and Germany, is actively engaged in PDX model research, often in collaboration with pharmaceutical companies.

The Asia-Pacific region, led by China and Japan, is experiencing a growing interest in PDX models as cancer research gains prominence and as the region’s healthcare landscape evolves. It benefits from a diverse patient population for creating PDX models that represent a broad range of genetic backgrounds.

In Latin America, PDX models are gradually gaining traction as the region focuses on enhancing its cancer research capabilities. Meanwhile, the Middle East and Africa regions are just beginning to explore the potential of PDX models, albeit at a slower pace, as they seek to contribute more significantly to cancer research and personalized medicine. These regional dynamics highlight the global nature of cancer research and the increasing role of PDX models in advancing our understanding of this complex disease and the development of tailored cancer treatments.

Recent Developments:

In December 2022, Crown Bioscience, a subsidiary of JSR Life Sciences, has formalized a comprehensive global licensing agreement with ERS Genomics Ltd. This agreement extends to Crown Bioscience full access to ERS’s foundational CRISPR/CAS9 patent portfolio, granting them the global utilization of CRISPR/CAS9 for genetic editing. With this pact, Crown Bioscience significantly enhances its genetic manipulation capabilities, opening the door to exploring gene editing within 3-dimensional models of patient-derived tumor organoids.

• In July 2022, GemPharmatech has formed a strategic licensing agreement with Charles River Laboratories, granting them exclusive distribution rights for GemPharmatech’s advanced NOD CRISPR Prkdc II2r gamma mouse lines in the North American region.

• In November 2021, Inotiv has confirmed the successful acquisition of Envigo RMS Holding Corporation, a prominent worldwide supplier of research models and services.

Key Players:

The Jackson Laboratory, Wuxi Apptec, JSR Corporation, Oncodesign Precision Medicine, Charles River Laboratories, Taconic Biosciences Inc, Xentec, Hera Biolabs, Urosphere, Pharmatest Services

Frequently Asked Questions

1) What is the projected market value of the Patient-Derived Xenograft (PDX) Model Market?

– The Patient-Derived Xenograft (PDX) Model Market is expected to reach a value of approximately USD 850 million by 2028

2) What is the estimated CAGR of the Patient-Derived Xenograft (PDX) Model Market over the 2023 to 2028 forecast period?

– The Patient-Derived Xenograft (PDX) Model Market is expected to grow at a CAGR of 15% from 2023 to 2028.

3) Who are the key players in the Patient-Derived Xenograft (PDX) Model Market?

– The Jackson Laboratory, Wuxi Apptec, JSR Corporation, Oncodesign Precision Medicine, Charles River Laboratories, Taconic Biosciences Inc, Xentec, Hera Biolabs, Urosphere, Pharmatest Services

Why Choose Us?

Insights into Market Trends: Global Market Studies reports provide valuable insights into market trends, including market size, segmentation, growth drivers, and market dynamics. This information helps clients make strategic decisions, such as product development, market positioning, and marketing strategies.

Competitor Analysis: Our reports provide detailed information about competitors, including their market share, product offerings, pricing, and competitive strategies. This data can be used to inform competitive strategies and to identify opportunities for growth and expansion.

Industry Forecasts: Our reports provide industry forecasts, which will inform your business strategies, such as investment decisions, production planning, and workforce planning. These forecasts can help you to prepare for future trends and to take advantage of growth opportunities.

Access to Industry Experts: Our solutions include contributions from industry experts, including analysts, consultants, and subject matter experts. This access to expert insights can be valuable for you to understand the market.

Time and Cost Savings: Our team at Global Market Studies can save you time and reduce the cost of conducting market research by providing comprehensive and up-to-date information in a single report, avoiding the need for additional market research efforts.

METHODOLOGY

At Global Market Studies, extensive research is done to create reports which have in-depth insights across all aspects of the market such as drivers, opportunities, challenges, restraints, market trends, regional insights, market segmentation, latest developments, key players for the forecast period. Multiple methods are used to derive both qualitative and quantitative information for the report:Silicon battery market by capacity (0–3,000 mah, 3,000–10,000 mah, 10,000–60,000 mah, and 60,000 mah & above), application (consumer electronics, automotive, aviation, energy, and medical devices), and region - 2023 to 2028 1

PRIMARY RESEARCH

Through surveys and interviews, primary research is sourced mainly from experts from the core and related industry. It includes distributors, manufacturers, Directors, C-Level Executives and Managers, alliances certification organisations across various segments of the markets value chain. Both the supply-side and demand-side is interviewed.

Silicon battery market by capacity (0–3,000 mah, 3,000–10,000 mah, 10,000–60,000 mah, and 60,000 mah & above), application (consumer electronics, automotive, aviation, energy, and medical devices), and region - 2023 to 2028 2

SECONDARY RESEARCH

Our sources of secondary research include Annual Reports, Journals, Press Releases, Company Websites, Paid Databases and our own Data Repository. They also include, investor presentations, certifies publications and articles by authorised regulatory bodies, trade directories and databases.

Silicon battery market by capacity (0–3,000 mah, 3,000–10,000 mah, 10,000–60,000 mah, and 60,000 mah & above), application (consumer electronics, automotive, aviation, energy, and medical devices), and region - 2023 to 2028 3

MARKET SIZE ESTIMATION

After extensive secondary and primary research, both the Bottom-up and Top-down methods are used to analyse the data. In the Bottom-up Approach, Company revenues across multiple segments are gathered to derive the percentage split per market segment. From this the Segment wise market size is derived to give the Total Market Size. In the Top-down Approach the reverse method is used where the Total Market Size is first derived from primary sources and is split into Market Segment, Regional Split and so on.

Silicon battery market by capacity (0–3,000 mah, 3,000–10,000 mah, 10,000–60,000 mah, and 60,000 mah & above), application (consumer electronics, automotive, aviation, energy, and medical devices), and region - 2023 to 2028 4Silicon battery market by capacity (0–3,000 mah, 3,000–10,000 mah, 10,000–60,000 mah, and 60,000 mah & above), application (consumer electronics, automotive, aviation, energy, and medical devices), and region - 2023 to 2028 5

Silicon battery market by capacity (0–3,000 mah, 3,000–10,000 mah, 10,000–60,000 mah, and 60,000 mah & above), application (consumer electronics, automotive, aviation, energy, and medical devices), and region - 2023 to 2028 6

DATA TRIANGULATION:

All statistics are collected through extensive secondary research and verified by interviews conducted with supply-side and demand-side in the primary research to ensure that both primary and secondary data percentages, statistics and findings corroborate.

Silicon battery market by capacity (0–3,000 mah, 3,000–10,000 mah, 10,000–60,000 mah, and 60,000 mah & above), application (consumer electronics, automotive, aviation, energy, and medical devices), and region - 2023 to 2028 7

Share

Get A Free Sample

Take a look at this complimentary sample which comprises of a variety of market data points such as trend analyses, market estimates, and forecasts. You can explore and evaluate it on your own.

Send me Free Sample

Or View Our License Options:

$3,850.00$5,850.00

Why

Industry Coverage: Global Market Studies has a broad range of industry coverage, spanning various sectors such as healthcare, technology, retail, automotive, and many others. This means that clients can rely on us to provide valuable insights into their respective industries, helping them make informed business decisions.

Our team of experts has years of experience in the market research industry, and they have honed their skills in data analysis, market forecasting, and trend analysis. They are also adept at using advanced research tools and techniques to gather and analyze data, providing clients with accurate and reliable insights.

We understand that each client has unique research needs, and we tailor our research solutions to meet their specific requirements. We work closely with our clients to understand their objectives and provide customized research solutions that address their business challenges.

We are committed to innovation and are constantly exploring new research methods and techniques to provide our clients with cutting-edge insights. This enables us to stay ahead of the curve and deliver the best possible research outcomes.

At Global Market Studies, our clients are at the center of everything we do. We pride ourselves on providing excellent customer service and support, and we are always available to address our clients’ concerns and questions.

83422+ Reports Delivered

Accurate market data is crucial to a successful business strategy. With an 85% + accuracy in all reports, makes us one of the best and most accurate firms in the world.

Need Customized Report ?Call Now

OVERVIEW

A recent report by Global Market Studies has revealed that the Patient-Derived Xenograft (PDX) Model Market in terms of revenue is estimated to reach $410 million in 2023 and will  reach a revenue of $850 million by 2028, growing at a CAGR of 15% to 2028.

The Patient-Derived Xenograft (PDX) Model Market pertains to a specialized sector within preclinical cancer research and drug development. It involves the transplantation of human tumor tissue, obtained directly from patients, into immunodeficient mice or other animal models. This creates living models that closely mimic the characteristics of the patient’s tumor, enabling researchers to study cancer behavior, test potential treatments, and advance the development of personalized medicine. The market encompasses services, products, and solutions related to the establishment, maintenance, and utilization of PDX models, contributing significantly to the field of oncology research and the development of tailored cancer therapies.

The Patient-Derived Xenograft (PDX) Model Market is primarily propelled by the imperative for personalized medicine and expedited drug development. Key drivers encompass the need to bridge the gap between preclinical and clinical research, enabling patient-specific therapy testing. Offerings include patient-derived tumor models, integration of omics data for comprehensive insights, and expansion into various therapeutic areas. These advancements foster innovation in oncology and beyond. PDX models also contribute to understanding tumor heterogeneity and drug resistance, ultimately shaping a more precise and effective healthcare landscape. In sum, the market’s core drivers and offerings drive forward the realms of personalized medicine, pharmaceutical research, and translational innovation.

Market Dynamics

Drivers:

The Patient-Derived Xenograft (PDX) Model Market is driven by several key factors. Firstly, there’s a growing demand for personalized cancer treatments, with PDX models enabling the testing of individual patient responses to various therapies. Additionally, traditional cell line models often fail to mimic the complexity of human tumors, enhancing the relevance of PDX models in oncology research. The global surge in cancer cases further propels the adoption of PDX models as researchers seek more accurate representations of patient-specific tumor behavior. Lastly, pharmaceutical companies and research institutions increasingly rely on PDX models to accelerate drug development, fostering innovation in precision medicine and cancer therapeutics. These drivers collectively underscore the growing significance of PDX models in advancing cancer research and treatment.

Opportunities:

The Patient-Derived Xenograft (PDX) Model Market offers a diverse range of offerings crucial for advancing cancer research and personalized medicine. Key offerings encompass the development and maintenance of PDX models, where human tumor tissues are transplanted into immunodeficient animals, creating living avatars of individual patient tumors. PDX model banks and associated data repositories enable researchers to access a wide variety of well-characterized models, enhancing the efficiency of oncology research. Additionally, services for drug efficacy testing, treatment response evaluation, and in-depth analysis of tumor behavior in a preclinical setting are vital for pharmaceutical companies and research institutions. The market also includes solutions for biobanking and data management, ensuring the secure storage and retrieval of PDX model samples and associated patient data. In essence, these offerings empower researchers and clinicians with essential tools to better understand cancer, optimize treatment strategies, and advance the field of oncology.

Restraints & Challenges:

The Patient-Derived Xenograft (PDX) Model Market faces several restraints and challenges. Firstly, the complex and costly process of establishing and maintaining PDX models can limit accessibility for smaller research institutions and companies. The time required for model development may not align with the urgency of certain research projects. Ethical considerations surrounding the use of animals in research pose regulatory and public relations challenges. Additionally, ensuring model reproducibility and reliability is paramount due to potential discrepancies between PDX models and original patient tumors. The variability and heterogeneity in human tumors further emphasize the need for careful validation and data interpretation. These challenges underscore the importance of continuous improvements and standardization within the PDX model field to fully harness their potential in advancing cancer research and personalized medicine.

Regional Information:

The Patient-Derived Xenograft (PDX) Model Market exhibits notable regional variations in adoption and research intensity. In North America, particularly the United States, PDX models are extensively used in preclinical research and oncology studies, supported by a robust pharmaceutical industry and research infrastructure. Europe, including the United Kingdom, France, and Germany, is actively engaged in PDX model research, often in collaboration with pharmaceutical companies.

The Asia-Pacific region, led by China and Japan, is experiencing a growing interest in PDX models as cancer research gains prominence and as the region’s healthcare landscape evolves. It benefits from a diverse patient population for creating PDX models that represent a broad range of genetic backgrounds.

In Latin America, PDX models are gradually gaining traction as the region focuses on enhancing its cancer research capabilities. Meanwhile, the Middle East and Africa regions are just beginning to explore the potential of PDX models, albeit at a slower pace, as they seek to contribute more significantly to cancer research and personalized medicine. These regional dynamics highlight the global nature of cancer research and the increasing role of PDX models in advancing our understanding of this complex disease and the development of tailored cancer treatments.

Recent Developments:

In December 2022, Crown Bioscience, a subsidiary of JSR Life Sciences, has formalized a comprehensive global licensing agreement with ERS Genomics Ltd. This agreement extends to Crown Bioscience full access to ERS’s foundational CRISPR/CAS9 patent portfolio, granting them the global utilization of CRISPR/CAS9 for genetic editing. With this pact, Crown Bioscience significantly enhances its genetic manipulation capabilities, opening the door to exploring gene editing within 3-dimensional models of patient-derived tumor organoids.

• In July 2022, GemPharmatech has formed a strategic licensing agreement with Charles River Laboratories, granting them exclusive distribution rights for GemPharmatech’s advanced NOD CRISPR Prkdc II2r gamma mouse lines in the North American region.

• In November 2021, Inotiv has confirmed the successful acquisition of Envigo RMS Holding Corporation, a prominent worldwide supplier of research models and services.

Key Players:

The Jackson Laboratory, Wuxi Apptec, JSR Corporation, Oncodesign Precision Medicine, Charles River Laboratories, Taconic Biosciences Inc, Xentec, Hera Biolabs, Urosphere, Pharmatest Services

Frequently Asked Questions

1) What is the projected market value of the Patient-Derived Xenograft (PDX) Model Market?

– The Patient-Derived Xenograft (PDX) Model Market is expected to reach a value of approximately USD 850 million by 2028

2) What is the estimated CAGR of the Patient-Derived Xenograft (PDX) Model Market over the 2023 to 2028 forecast period?

– The Patient-Derived Xenograft (PDX) Model Market is expected to grow at a CAGR of 15% from 2023 to 2028.

3) Who are the key players in the Patient-Derived Xenograft (PDX) Model Market?

– The Jackson Laboratory, Wuxi Apptec, JSR Corporation, Oncodesign Precision Medicine, Charles River Laboratories, Taconic Biosciences Inc, Xentec, Hera Biolabs, Urosphere, Pharmatest Services

Why Choose Us?

Insights into Market Trends: Global Market Studies reports provide valuable insights into market trends, including market size, segmentation, growth drivers, and market dynamics. This information helps clients make strategic decisions, such as product development, market positioning, and marketing strategies.

Competitor Analysis: Our reports provide detailed information about competitors, including their market share, product offerings, pricing, and competitive strategies. This data can be used to inform competitive strategies and to identify opportunities for growth and expansion.

Industry Forecasts: Our reports provide industry forecasts, which will inform your business strategies, such as investment decisions, production planning, and workforce planning. These forecasts can help you to prepare for future trends and to take advantage of growth opportunities.

Access to Industry Experts: Our solutions include contributions from industry experts, including analysts, consultants, and subject matter experts. This access to expert insights can be valuable for you to understand the market.

Time and Cost Savings: Our team at Global Market Studies can save you time and reduce the cost of conducting market research by providing comprehensive and up-to-date information in a single report, avoiding the need for additional market research efforts.

METHODOLOGY

At Global Market Studies, extensive research is done to create reports which have in-depth insights across all aspects of the market such as drivers, opportunities, challenges, restraints, market trends, regional insights, market segmentation, latest developments, key players for the forecast period. Multiple methods are used to derive both qualitative and quantitative information for the report:Silicon battery market by capacity (0–3,000 mah, 3,000–10,000 mah, 10,000–60,000 mah, and 60,000 mah & above), application (consumer electronics, automotive, aviation, energy, and medical devices), and region - 2023 to 2028 1

PRIMARY RESEARCH

Through surveys and interviews, primary research is sourced mainly from experts from the core and related industry. It includes distributors, manufacturers, Directors, C-Level Executives and Managers, alliances certification organisations across various segments of the markets value chain. Both the supply-side and demand-side is interviewed.

Silicon battery market by capacity (0–3,000 mah, 3,000–10,000 mah, 10,000–60,000 mah, and 60,000 mah & above), application (consumer electronics, automotive, aviation, energy, and medical devices), and region - 2023 to 2028 2

SECONDARY RESEARCH

Our sources of secondary research include Annual Reports, Journals, Press Releases, Company Websites, Paid Databases and our own Data Repository. They also include, investor presentations, certifies publications and articles by authorised regulatory bodies, trade directories and databases.

Silicon battery market by capacity (0–3,000 mah, 3,000–10,000 mah, 10,000–60,000 mah, and 60,000 mah & above), application (consumer electronics, automotive, aviation, energy, and medical devices), and region - 2023 to 2028 3

MARKET SIZE ESTIMATION

After extensive secondary and primary research, both the Bottom-up and Top-down methods are used to analyse the data. In the Bottom-up Approach, Company revenues across multiple segments are gathered to derive the percentage split per market segment. From this the Segment wise market size is derived to give the Total Market Size. In the Top-down Approach the reverse method is used where the Total Market Size is first derived from primary sources and is split into Market Segment, Regional Split and so on.

Silicon battery market by capacity (0–3,000 mah, 3,000–10,000 mah, 10,000–60,000 mah, and 60,000 mah & above), application (consumer electronics, automotive, aviation, energy, and medical devices), and region - 2023 to 2028 4Silicon battery market by capacity (0–3,000 mah, 3,000–10,000 mah, 10,000–60,000 mah, and 60,000 mah & above), application (consumer electronics, automotive, aviation, energy, and medical devices), and region - 2023 to 2028 5

Silicon battery market by capacity (0–3,000 mah, 3,000–10,000 mah, 10,000–60,000 mah, and 60,000 mah & above), application (consumer electronics, automotive, aviation, energy, and medical devices), and region - 2023 to 2028 6

DATA TRIANGULATION:

All statistics are collected through extensive secondary research and verified by interviews conducted with supply-side and demand-side in the primary research to ensure that both primary and secondary data percentages, statistics and findings corroborate.

Silicon battery market by capacity (0–3,000 mah, 3,000–10,000 mah, 10,000–60,000 mah, and 60,000 mah & above), application (consumer electronics, automotive, aviation, energy, and medical devices), and region - 2023 to 2028 7

Related Research Reports